Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.14365/5558
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Siriratnam, Pakeeran | - |
dc.contributor.author | Sanfilippo, Paul | - |
dc.contributor.author | van der Walt, Anneke | - |
dc.contributor.author | Sharmin, Sifat | - |
dc.contributor.author | Foong, Yi Chao | - |
dc.contributor.author | Yeh, Wei Zhen | - |
dc.contributor.author | Zhu, Chao | - |
dc.date.accessioned | 2024-10-25T15:17:49Z | - |
dc.date.available | 2024-10-25T15:17:49Z | - |
dc.date.issued | 2024 | - |
dc.identifier.issn | 0022-3050 | - |
dc.identifier.issn | 1468-330X | - |
dc.identifier.uri | https://doi.org/10.1136/jnnp-2024-334090 | - |
dc.identifier.uri | https://hdl.handle.net/20.500.14365/5558 | - |
dc.description.abstract | Background Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD. Methods This was a multicentre, international, retrospective cohort study using the MSBase registry. Recurrent relapse risk was assessed using an Andersen-Gill model and risk of first relapse was evaluated using a Cox proportional hazards model. Covariates that putatively influence relapse risk included demographic factors, clinical characteristics and immunosuppressive therapies; the latter was assessed as a time-varying covariate. Results A total of 398 patients (246 AQP4-IgG NMOSD and 152 seronegative NMOSD) were included. The AQP4-IgG NMOSD and seronegative NMOSD patients did not significantly differ by age at disease onset, ethnicity or annualised relapse rate. Both low-efficacy and high-efficacy immunosuppressive therapies were associated with significant reductions in recurrent relapse risk, with notably greater protection conferred by high-efficacy therapies in both AQP4-IgG NMOSD (HR 0.27, 95% CI 0.15 to 0.49, p<0.001) and seronegative NMOSD (HR 0.21, 95% CI 0.08 to 0.51, p<0.001). Longer disease duration (HR 0.97, 95% CI 0.95 to 0.99, p<0.001) and male sex (HR 0.52, 95% CI 0.34 to 0.84, p=0.007) were additional protective variables in reducing the recurrent relapse risk for the AQP4-IgG NMOSD group. Conclusion Although further studies are needed to improve our understanding of seronegative NMOSD, our findings underscore the importance of aggressive treatment with high-efficacy immunotherapies in both NMOSD subtypes, regardless of serostatus. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Bmj Publishing Group | en_US |
dc.relation.ispartof | Journal of neurology neurosurgery and psychiatry | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | MULTIPLE SCLEROSIS | en_US |
dc.subject | NEUROIMMUNOLOGY | en_US |
dc.subject | IMMUNOLOGY | en_US |
dc.subject | MEDICINE | en_US |
dc.subject | HEALTH ECONOMICS | en_US |
dc.subject | Optica Spectrum Disorder | en_US |
dc.subject | Neuromyelitis-Optica | en_US |
dc.subject | Double-Blind | en_US |
dc.subject | Efficacy | en_US |
dc.subject | Safety | en_US |
dc.subject | Azathioprine | en_US |
dc.subject | Satralizumab | en_US |
dc.subject | Rituximab | en_US |
dc.subject | Outcomes | en_US |
dc.title | Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study | en_US |
dc.type | Article | en_US |
dc.type | Article; Early Access | en_US |
dc.identifier.doi | 10.1136/jnnp-2024-334090 | - |
dc.identifier.pmid | 39231582 | en_US |
dc.identifier.scopus | 2-s2.0-85204235831 | en_US |
dc.department | İzmir Ekonomi Üniversitesi | en_US |
dc.authorid | Siriratnam, Pakeeran/0000-0003-4751-2102 | - |
dc.authorid | Foschi, Matteo/0000-0002-0321-7155 | - |
dc.authorwosid | Foschi, Matteo/ABR-7231-2022 | - |
dc.authorwosid | Siriratnam, Pakeeran/AGX-6343-2022 | - |
dc.authorwosid | Monif, Mastura/L-4124-2019 | - |
dc.authorwosid | Soysal, Aysun/AAX-7696-2021 | - |
dc.authorscopusid | 57210635745 | - |
dc.authorscopusid | 6701687565 | - |
dc.authorscopusid | 35079672200 | - |
dc.authorscopusid | 55028512500 | - |
dc.authorscopusid | 55258457800 | - |
dc.authorscopusid | 57201885527 | - |
dc.authorscopusid | 57348355200 | - |
dc.identifier.wos | WOS:001309611300001 | en_US |
dc.institutionauthor | … | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
item.grantfulltext | none | - |
item.openairetype | Article | - |
item.openairetype | Article; Early Access | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.cerifentitytype | Publications | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.